Clinical trials: Peripheral Arterial Disease
Peripheral Artery Disease
BRight Pharmacokinetic Study
The BRight PK Study is a prospective, single-arm, open-label, non-blinded, non-randomized study, which goal is to assess the pharmacokinetic profile of the BRight drug-coated balloon at different time points after the balloon…
- Trial name
- NCT06065345
- Testing
- BRight DCB
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Biotronik CRC Inc.
Peripheral Artery Disease
Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients
The purpose of this study is to evaluate whether PET/CT-RGD or MIBI can be used for the angiogenesis assessment of NL003 in PAD patients.
- Trial name
- NCT05968118
- Testing
- NL003
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Peripheral Artery Disease
Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)
The purpose of this study is to determine if it is safe and feasible to apply PRT-201 to the adventitia of arteries following successful angioplasty (PTA).
- Trial name
- NCT01616290
- Testing
- PRT-201
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Proteon Therapeutics
Peripheral Arterial Disease
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- NCT00955617
- Testing
- Contrast-enhanced MRA - Imaging examination
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Guerbet
Peripheral Arterial Disease
Kaitoh Atherectomy FIH
This is a prospective, multi-center and single-arm clinical study to assess the initial safety and effectiveness of the Kaitoh Atherectomy System for the treatment of de novo and/or restenotic lesion(s) in the peripheral arteries.
- Trial name
- NCT05873452
- Testing
- Kaitoh Atherectomy System
- Where
- 2 sites in New Zealand
- Volunteers
- 9 people
- Sponsor
- Terumo Medical Corporation
Peripheral Arterial Disease
Evaluation of the Pantheris Atherectomy System
A non-randomized, prospective, global clinical trial of the Avinger Pantheris System, an atherectomy device that provides directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque in diseased…
- Trial name
- VISION (NCT01937351)
- Testing
- Pantheris System
- Where
- 21 sites in United States, Germany
- Volunteers
- 162 people
- Sponsor
- Avinger, Inc.
Arterial Occlusive Diseases, Peripheral Vascular Diseases
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).
- Conditions
- Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
- Trial name
- NCT00073554
- Testing
- Alfimeprase
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- ARCA Biopharma, Inc.
Peripheral Arterial Disease
Near Infrared Spectroscopy Imaging of Change in Tissue Oxygenation to Assess Peripheral Artery Disease
This is a proof-of-concept study with exploratory objective to assess whether superficial tissue oxygenation patterns measured by Snapshot NIRS, in conjunction with the Provocative Elevation Maneuver of the Lower Extremity…
- Trial name
- NCT07397494
- Testing
- Observational study only.
- Volunteers
- 200 people
- Sponsor
- Kent Imaging Inc
Peripheral Arterial Disease
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
- Trial name
- ATTAIN-PAD (NCT07223593)
- Testing
- Orforglipron
- Where
- 169 sites in United States, Argentina and 16 more
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
SELUTION4BTK Trial
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in…
- Trial name
- NCT05055297
- Testing
- SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA)
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 376 people
- Sponsor
- M.A. Med Alliance S.A.
Peripheral Arterial Disease, Critical Limb Ischemia
A Study of the TEmporary Spur StEnt System for the Treatment of Lesions Located in the InfraPoplitEal ARteries Using a LIMUS-base DCB
This is a non-randomized, prospective, single center pilot study designed to evaluate the safety of the Temporary Spur Stent System to treat patients with infrapopliteal arterial disease, when used in conjunction with a…
- Trial name
- DEEPER LIMUS (NCT04162418)
- Testing
- Temporary Spur Stent System
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- ReFlow Medical, Inc.
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for…
- Trial name
- NCT04915950
- Testing
- Temanogrel
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pfizer
Peripheral Arterial Disease, Claudication
Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease
The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment with the Cotavance™ drug-eluting balloon…
- Trial name
- DEFINITIVE AR (NCT01366482)
- Testing
- Cotavance Drug-Eluting Balloon, TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon
- Where
- Belgium
- Volunteers
- 121 people
- Sponsor
- Medtronic Endovascular
Peripheral Artery Disease
Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries
The research study is designed to assess the technical feasibility and safety of percutaneous administration of vonapanitase to the superficial femoral or popliteal artery in patients with PAD.
- Trial name
- NCT02953496
- Testing
- vonapanitase
- Where
- United States
- Sponsor
- Proteon Therapeutics
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Peripheral Artery Disease
Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran
This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial
- Trial name
- NCT04197323
- Testing
- Alprostadil liposomes for injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Peripheral Artery Disease
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD).
- Trial name
- NCT02887859
- Testing
- Human Acellular Vessel (HAV)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Humacyte, Inc.
Arterial Occlusive Diseases
Crossing Atheroma or Thrombus With ByCross Device for Revascularization of Peripheral Arteries of Diameter ≥ 3mm
The aim of the study is to demonstrate safety and effectiveness of ByCross Rotational and Aspiration device used for revascularization of total or sub-total occluded peripheral arterial vessels equal to or larger than 3mm in…
- Trial name
- NCT03724279
- Testing
- ByCross Atherectomy and Thrombectomy
- Where
- 2 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Taryag Medical Ltd.
Critical Limb Ischemia
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia
The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain…
- Trial name
- NCT06359912
- Testing
- EPCs, Clinical standard treatment (CST)
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Peripheral Arterial Disease
Study of NMB Drug Ejecting Balloon for Peripheral Arteries
The purpose of this study is to demonstrate the Safety and effectiveness of the use of NMB's drug ejecting balloon for the treatment of de novo and restenotic lesions in peripheral arterial disease.
- Trial name
- NCT01646801
- Testing
- NMB Balloon Catheter
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- N.M.B. Medical Applications Ltd